Targeting FGFR inhibition in cholangiocarcinoma - ScienceDirect
Phase 2 study of pembrolizumab in patients with advanced rare cancers | Journal for ImmunoTherapy of Cancer
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Life | Free Full-Text | Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
First-in-human Phase I “Basket” Study of Debio 1347 (CH5183284), a Novel FGFR Inhibitor in Patients with FGFR Genomically
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
New clinical trial designs in the era of precision medicine
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Frontiers | Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma - ScienceDirect
Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
Is Debiopharm Group late reporting EU clinical trials?
Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
PDF) New clinical trial designs in the era of Precision Medicine
Cancers | Free Full-Text | Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
2019 ASCO Annual Meeting Proceedings Immuno-Oncology Abstracts | Journal of Clinical Oncology
PDF) New clinical trial designs in the era of Precision Medicine
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
